BMS-986205 — Competitive Intelligence Brief

BMS-986205 (BMS-986205) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NLRP3 inflammasome inhibitor. Area: Immunology.

phase 3 NLRP3 inflammasome inhibitor NLRP3 Immunology Biologic

Target snapshot

BMS-986205 (BMS-986205) — Bristol-Myers Squibb. BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BMS-986205 TARGET	BMS-986205	Bristol-Myers Squibb	phase 3	NLRP3 inflammasome inhibitor	NLRP3
BMS-986278	BMS-986278	Bristol-Myers Squibb	phase 3	NLRP3 inflammasome inhibitor	NLRP3
Both deferoxamine mesylate and colchicine	Both deferoxamine mesylate and colchicine	The George Institute	phase 3	Iron chelator + anti-inflammatory combination	Labile iron (deferoxamine); microtubule polymerization and NLRP3 inflammasome (colchicine)
Al(OH)3	Al(OH)3	Janssen Vaccines & Prevention B.V.	phase 3	Vaccine adjuvant	NLRP3 inflammasome; antigen-presenting cells

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NLRP3 inflammasome inhibitor class)

1. Bristol-Myers Squibb · 2 drugs in this class
2. Aquinox Pharmaceuticals (Canada) Inc. · 1 drug in this class
3. Astellas Pharma Inc · 1 drug in this class